Abstract:Targeting specific ubiquitin E3 ligase for degradation of disease-driven protein has recently been an important concept for cancer therapy, as exemplified by the case of thalidomide for the treatment of multiple myeloma. E7070, an aryl sulfonamide drug, exhibited anticancer activity by targeting the E3 ligase receptor DCAF15, with RBM39 as the only known substrate. Exploration of additional substrates of E7070 would facilitate elucidation of its mechanism of actions. To this end, we used a strategy combing pSILAC method with two complementary digestion approaches (LysC-Trypsin and LysN-LysArgiNase) to accurately monitor the protein turnover and increase the depth of proteome profiling. Systematically, we showed that E7070 treatment changed turnover rates of 868 proteins (1.5 fold change and p-value <.05). Several proteins displayed accelerated turnover indicating they were potential new substrates of E7070, among which, pre-mRNA splicing factor 39 (PRPF39) had been reported to be overexpressed in certain cancers. We further demonstrated that PRPF39 was ubiquitinated and degraded by E7070 in a DCAF15-dependent manner, and represented a new bona fide substrate of E7070. The degradation of PRPF39 might also be contributed to the anticancer activity of E7070. SIGNIFICANCE: Identification of degraded substrates is difficult because protein abundance is a comprehensive result regulated by protein production and degradation at the same time. Pulsed SILAC (pSILAC), a method to measure protein turnover, would provide higher sensitivity than total protein quantification. In addition, some peptide sequences are not amenable to MS analysis after LysC-Trypsin digestion. LysN-LysargiNase, as a mirror protease combination of LysC-Trypsin, can be complementary for peptide identification with LysC-Trypsin. By combining pSILAC with two complementary digestion approaches (LysC-Trypsin and LysN-LysArgiNase), we systematically investigated E7070-dependent protein degradation. As a result, we found several potential degradation substrates of E7070 including PRPF39. Further, by exploiting a series of biological assays, we demonstrated that E7070 can lead to the ubiquitination and proteasomal degradation of PRPF39 by promoting the recruitment of PRPF39 to the CUL4-DCAF15 E3 ubiquitin ligase.

A Proteomics Strategy to Identify Substrates of LNX, a PDZ Domain Containing E3 Ubiquitin Ligase

A ubiquitin-specific, proximity-based labeling approach for the identification of ubiquitin ligase substrates

Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates

Quantitative Proteomics Combined with Two Genetic Strategies for Screening Substrates of Ubiquitin Ligase Hrt3.

Screening E3 Substrates Using a Live Phage Display Library.

An Integrated Bioinformatics Platform for Investigating the Human E3 Ubiquitin Ligase-Substrate Interaction Network

Integrative Proximal-Ubiquitomics Profiling for Deubiquitinase and E3 Ligase Substrate Discovery Applied to USP30

Identifying the Substrate Proteins of E3 Ubiquitin Ligase by Orthogonal Ubiquitin Transfer (OUT)

Psilac Method Coupled with Two Complementary Digestion Approaches Reveals PRPF39 As a New E7070-dependent DCAF15 Substrate.

Functional Dissection of a HECT Ubiquitin E3 Ligase

A Cell-Based High-Throughput Screening Method Based on a Ubiquitin-Reference Technique for Identifying Modulators of E3 Ligases.

High‐Throughput Discovery of Substrate Peptide Sequences for E3 Ubiquitin Ligases Using a cDNA Display Method

A Multidimensional Characterization of E3 Ubiquitin Ligase and Substrate Interaction Network

Identification Of Ubiquitin Target Proteins Using Cell-Based Arrays

Ubiquitin ligase LNX1 promotes the ubiquitination and degradation of exogenous PBK

Engineering the Orthogonal Ubiquitin E1-E2 Pairs for Identification of K27 Chain Linkage Substrates

Structure-guided engineering enables E3 ligase-free and versatile protein ubiquitination via UBE2E1

Targeting Cullin-RING E3 ligases for anti-cancer therapy:efforts on drug discovery

A General Strategy for Discovery of Inhibitors and Activators of RING and U-box E3 Ligases with Ubiquitin Variants

An Activity-Based Probe Developed by a Sequential Dehydroalanine Formation Strategy Targets HECT E3 Ubiquitin Ligases

Profiling lysine ubiquitination by selective enrichment of ubiquitin remnant-containing peptides.